Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies.

Daniel L. Adams(Creatv MicroTech (United States)), Martin J. Edelman(Fox Chase Cancer Center), Massimo Cristofanilli(Cornell University), Susan Tsai(The Ohio State University Wexner Medical Center), R. Katherine Alpaugh(Fox Chase Cancer Center), Saranya Chumsri(Jacksonville College), Raymond C. Bergan(University of Nebraska Medical Center), Rena G. Lapidus(University of Maryland, Baltimore), Monica S. Charpentier(University of Maryland, Baltimore), Stuart S. Martin(University of Maryland, Baltimore), Cha‐Mei Tang(Creatv MicroTech (United States))
Journal of Clinical Oncology
May 20, 2015
10.1200/jco.2015.33.15_suppl.11095
Cited by 4

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
The Landscape of Targeted Therapies in TNBC
|Cancers|2020|448